Influenza – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Influenza Market Outlook and Forecast

Thelansis’s "Influenza Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Influenza treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Influenza Overview

Influenza is an acute respiratory viral infection characterized by continual antigenic evolution, driving recurrent seasonal epidemics and creating persistent pandemic risk. Seasonal vaccination remains the cornerstone of prevention, but circulating viruses can continue to drift after strain selection, requiring annual formulation updates; for 2026–27, all three U.S. vaccine components were updated. Antivirals including oseltamivir and baloxavir remain effective treatment options when used appropriately, with greatest benefit from early initiation, although treatment remains particularly time-sensitive in uncomplicated outpatient disease. The vaccine landscape is now entering a new phase: on August 5, 2026, the FDA approved MFLUSIVA, Moderna’s mRNA influenza vaccine, for adults aged 50 years and older, providing the first commercial validation of an mRNA seasonal influenza platform in the United States. Its platform can accommodate seasonal strain updates without redesigning the underlying delivery system. In parallel, universal and broadly protective vaccines targeting conserved influenza antigens remain an important research frontier. For stakeholders, influenza innovation is shifting from simply improving annual strain matching toward rapidly updateable platforms, broader immunity, and potentially more durable protection across seasons and viral subtypes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more...